Jci_page_head_homepage_01 Jci_page_head_homepage_02
Stuart E. Turvey, Eric Swart, Maria C. Denis, Umar Mahmood, Christophe Benoist, Ralph Weissleder, Diane Mathis
Published in Volume 115, Issue 9
J Clin Invest. 2005; 115(9):2454–2461 doi:10.1172/JCI25048
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 6

Noninvasive imaging of pancreatic inflammation can predict clinical response to anti-CD3 immunotherapy. Female NOD mice with very recent onset of diabetes were treated with either anti-CD3 or control F(ab′)2 fragments for 5 consecutive days as described in Methods. MRI was performed 24 hours after MNP injection on days 4, 8, and 18 after starting mAb immunotherapy. (A) Results from long-term responders rendered normoglycemic following F(ab′)2 treatment (triangles) are compared with those of mice failing to respond to therapy, i.e., anti-CD3 nonresponders (squares) and control antibody nonresponders (circles). Since some mice remained profoundly hyperglycemic for over 3 weeks in this experimental series, pancreas/muscle T2 ratio is presented to control for nonspecific alterations in MRI parameters induced by these global metabolic changes. Groups represent the following number of mice: day 4: responders, n = 4, nonresponders, n = 6; day 8: responders, n = 6, nonresponders, n = 4, control mAb treated, n = 3; day 18: responders, n = 4, nonresponders, n = 6. (B) Pancreas/muscle T2 ratio is plotted against the serum glucose measured at the time of scanning (n = 33), showing no correlation between pancreatic inflammation as determined by MNP-MRI and serum glucose.